NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 83 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q1 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,206,442 | -17.7% | 1,014,567 | +0.8% | 0.00% | – |
| Q2 2023 | $3,895,023 | +41.5% | 1,006,466 | +1.3% | 0.00% | – |
| Q1 2023 | $2,752,510 | +159096.6% | 993,686 | +3.4% | 0.00% | – |
| Q4 2022 | $1,729 | -99.9% | 960,868 | +0.6% | 0.00% | – |
| Q3 2022 | $2,024,000 | -20.8% | 955,069 | +0.5% | 0.00% | – |
| Q2 2022 | $2,557,000 | +12.0% | 950,779 | +80.7% | 0.00% | – |
| Q1 2022 | $2,284,000 | -11.0% | 526,306 | +6.3% | 0.00% | – |
| Q4 2021 | $2,565,000 | +8.3% | 495,198 | +28.3% | 0.00% | – |
| Q3 2021 | $2,369,000 | +258.9% | 385,871 | +490.0% | 0.00% | – |
| Q2 2021 | $660,000 | – | 65,397 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $16,298,000 | 8.49% |
| Madrona Venture Group, LLC | 6,020,770 | $31,188,000 | 5.89% |
| ArchPoint Investors | 1,449,551 | $7,509,000 | 2.23% |
| Ally Bridge Group (NY) LLC | 1,225,060 | $6,346,000 | 2.22% |
| Affinity Asset Advisors, LLC | 1,049,721 | $5,438,000 | 1.98% |
| Tikvah Management LLC | 1,231,835 | $6,381,000 | 1.78% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $10,360,000 | 0.82% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $1,356,000 | 0.74% |
| Perceptive Advisors | 18,222,302 | $94,390,000 | 0.73% |
| SPHERA FUNDS MANAGEMENT LTD. | 800,000 | $4,144,000 | 0.46% |